Plain-English translation of NCT06592599 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for advanced nasopharyngeal cancer (a cancer that starts in the upper throat behind the nose) that is caused by Epstein-Barr virus. The treatment combines three medications — gemcitabine, docetaxel, and — given before radiation therapy, along with additional medications afterward. Researchers want to see if this combination is safe and whether it helps patients with this type of cancer live longer.
Nasopharyngeal cancer is a serious disease, and patients with advanced stages have limited treatment options. This trial exists to test whether adding (a newer type of medication that helps the immune system fight cancer) to traditional chemotherapy and radiation might work better than standard treatment alone.
You likely qualify if…
You likely don't qualify if…
You would receive three cycles of intravenous chemotherapy medications (one cycle every 21 days), followed by six to seven weeks of daily radiation therapy combined with weekly chemotherapy infusions. After that, you would take an oral medication twice daily for one year and receive additional intravenous infusions every three weeks for nine doses. Throughout this time, you would have regular blood tests and imaging scans to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Stanford University
Enrollment target
~24 participants
Started
September 2024
Primary completion
January 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Elizabeth Winters
Stanford University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.